CAMPATH: from concept to clinic.
Lymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has established it as a licensed drug for the management of chr...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2005
|
| _version_ | 1797101655450189824 |
|---|---|
| author | Waldmann, H Hale, G |
| author_facet | Waldmann, H Hale, G |
| author_sort | Waldmann, H |
| collection | OXFORD |
| description | Lymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has established it as a licensed drug for the management of chronic lymphocyte leukaemia. Short-term therapy with alemtuzumab has demonstrated long-term benefit in a number of autoimmune conditions. This drug has the potential to facilitate recruitment of tolerance processes so enabling drug minimization in transplantation, autoimmune and hypersensitivity diseases. |
| first_indexed | 2024-03-07T05:54:53Z |
| format | Journal article |
| id | oxford-uuid:ea30930e-b8c6-4b36-b792-9e3997bfc12f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:54:53Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:ea30930e-b8c6-4b36-b792-9e3997bfc12f2022-03-27T10:59:53ZCAMPATH: from concept to clinic.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ea30930e-b8c6-4b36-b792-9e3997bfc12fEnglishSymplectic Elements at Oxford2005Waldmann, HHale, GLymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has established it as a licensed drug for the management of chronic lymphocyte leukaemia. Short-term therapy with alemtuzumab has demonstrated long-term benefit in a number of autoimmune conditions. This drug has the potential to facilitate recruitment of tolerance processes so enabling drug minimization in transplantation, autoimmune and hypersensitivity diseases. |
| spellingShingle | Waldmann, H Hale, G CAMPATH: from concept to clinic. |
| title | CAMPATH: from concept to clinic. |
| title_full | CAMPATH: from concept to clinic. |
| title_fullStr | CAMPATH: from concept to clinic. |
| title_full_unstemmed | CAMPATH: from concept to clinic. |
| title_short | CAMPATH: from concept to clinic. |
| title_sort | campath from concept to clinic |
| work_keys_str_mv | AT waldmannh campathfromconcepttoclinic AT haleg campathfromconcepttoclinic |